<DOC>
	<DOCNO>NCT00956345</DOCNO>
	<brief_summary>This trial conduct Europe , Japan United States America ( USA ) . The aim clinical trial investigate safety pharmacokinetics ( determination concentration administer medication blood time ) Pegylated Recombinant Factor IX ( nonacog beta pegol ) Non-Bleeding Patients Haemophilia B .</brief_summary>
	<brief_title>Safety 40K Pegylated Recombinant Factor IX Non-Bleeding Patients With Haemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Diagnosed haemophilia B ( baseline level Factor IX less equal 2 % ) History least 150 exposure day Factor IX product Body Mass Index ( BMI ) 30.0 kg/m2 ( inclusive ) History Factor IX inhibitor Platelet count le 50,000 platelets/microlitre ( assessed laboratory ) Kidney liver dysfunction Scheduled surgery require Factor IX replacement therapy , trial period</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>